PurMinds NeuroPharma

Pursuing breakthrough solutions to devastating neurological disorders.

Recent News

PurMinds NeuroPharma Selected to Present at the 2024 OBIO Investment Summit
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 6, 2024) - PurMinds NeuroPharma Inc. ("PurMinds™" or the "Company"), a clinical-stage neuroscience company dedicated to the development of innovative therapies for neurological and neurodegenerative disorders, is thrilled to announce its selection as one of the prestigious presenters at the upcoming 2024 OBIO® Investment Summit. The OBIO® Investment Summit, renowned for its focus on fostering growth and innovation in the healthcare sector, presents an ideal platform for PurMinds to showcase its cutting-edge...
2024-02-06 8:30 AM EST
PurMinds Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - December 14, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, is pleased to announce that its management team, including Chief Executive Officer Janet Qi and Chief Scientific Officer Dr. Alan Kozikowski, will be attending the 42nd Annual J.P. Morgan Healthcare Meeting, taking place on January 08-11, 2024, in San...
2023-12-14 8:30 AM EST
PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 29, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, today announced that Dr. Amy Reichelt, Ph.D., the company's Chief Innovation Officer, will be speaking at the Analytical Cannabis Educational Webinar December 14th at 9am PST/ 12PM EST/5PM GMT.This webinar will explore the intersection of neuroscience and psychedelics,...
2023-11-29 8:49 AM EST
PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 9, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, today announced the appointment of one of the world's leading drug designer, Professor Alan Kozikowski, Ph.D., to the role of Chief Scientific Officer ("CSO"), and the appointment of experienced pharma and technology transfer expert, Professor Max Arella, Ph.D.,...
2023-11-09 8:30 AM EST
PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 7, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, is pleased to announce that under its Health Canada Dealer's License for Controlled Drugs and Substances ("Dealer's License"), it has tripled its psilocybin mushroom propagation yields and has a growing inventory of three dried psilocybe cubensis strains.Psilocybin...
2023-11-07 8:30 AM EST
PurMinds(TM) NeuroPharma Awarded Synthetic Psilocybin API Import Permit from Health Canada to Develop GMP-Compliant Psychedelic Drug Product Formulations for Clinical Trial Supply
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 11, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, is pleased to announce that under its Health Canada Schedule 1 Dealer's License for Controlled Drugs and Substances ("Dealer's License"), it has been awarded its first Psychedelic Import Permit from the Controlled Substances Directorate of Health Canada.Revenue Producing...
2023-10-11 9:04 AM EDT
PurMinds Acquires Novel Chemical Entity HDAC6 Inhibitor for Neurological Disorders
Toronto, Ontario--(Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity. Drugs that inhibit the molecular target HDAC6 are a novel class of therapeutics...
2023-09-28 8:30 AM EDT
PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski to the Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - September 8, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a Canadian neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders marred by neurodegeneration, today announced the appointment of one of the world's leading drug designer, Professor Alan Kozikowski, Ph.D., to the Company's Scientific Advisory Board ("SAB"). Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology...
2023-09-08 8:30 AM EDT

PurMinds NeuroPharma

Recent News

Get News by Email

RSS Feeds

Tell Us Your Story

Cookie Settings

Get News by Email

RSS Feeds

Tell Us Your Story